Last update 01 Nov 2024
Girocitinib
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC17H18N4O3 |
InChIKeyZFQNHUSKKDBFHY-GRYCIOLGSA-N |
CAS Registry2222137-79-1 |
Related
18
Clinical Trials associated with GirocitinibA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria With Inadequate Controll to Second Generation H1-antihistamines
A Phase 3, Randomized, Double-Blind, Positive-controlled, Head-to-Head Monotherapy Study Comparing TLL-018 to Tofacitinib in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
评价TLL-018与托法替布头对头单药治疗对bDMARDs疗效不足或不耐受的活动性类风湿关节炎患者的疗效和安全性的随机、双盲、阳性对照的III期研究
[Translation] A randomized, double-blind, active-controlled phase III study to evaluate the efficacy and safety of TLL-018 versus tofacitinib monotherapy in patients with active rheumatoid arthritis who have insufficient efficacy or intolerance to bDMARDs
100 Clinical Results associated with Girocitinib
Login to view more data
100 Translational Medicine associated with Girocitinib
Login to view more data
100 Patents (Medical) associated with Girocitinib
Login to view more data
100 Deals associated with Girocitinib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Urticaria | Phase 3 | CN | 19 Mar 2024 | |
| Rheumatoid Arthritis | Phase 3 | CN | 14 Nov 2023 | |
| Plaque psoriasis | Phase 2 | US | 19 Jan 2023 | |
| Psoriasis | Phase 2 | CN | - | |
| Dermatitis, Atopic | Phase 1 | CN | 10 Jul 2023 | |
| Colitis, Ulcerative | Phase 1 | US | 30 Dec 2022 | |
| Systemic Lupus Erythematosus | IND Approval | CN | 21 Aug 2023 | |
| Inflammation | Preclinical | US | 26 Jan 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05133297 (EULAR2023) Manual  | Phase 2 | 101 | (czvdnijayi) = ohhmwkdtvw yljyslrbwz (uwmjlvlcbq, 28.42 - 67.58) View more | Positive | 31 May 2023 | ||
(czvdnijayi) = ehvdudjupi yljyslrbwz (uwmjlvlcbq, 47.10 - 83.67) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free